Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)

Tipranks - Tipranks - Wed Apr 1, 12:00PM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX).

End of Quarter Sale - 50% Off TipRanks

Entrada Therapeutics Inc (TRDA)

William Blair analyst Myles Minter maintained a Buy rating on Entrada Therapeutics Inc today. The company’s shares closed last Tuesday at $12.40.

According to TipRanks.com, Minter is a top 100 analyst with an average return of 34.2% and a 60.4% success rate. Minter covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, CAMP4 Therapeutics Corporation, and Neumora Therapeutics, Inc. ;'>

Entrada Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $20.00, which is a 65.0% upside from current levels. In a report issued on March 23, TD Cowen also maintained a Buy rating on the stock.

See the top stocks recommended by analysts >>

Apellis Pharmaceuticals (APLS)

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $41.00. The company’s shares closed last Tuesday at $40.27.

According to TipRanks.com, Frommer is a 2-star analyst with an average return of -0.2% and a 50.4% success rate. Frommer covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Bicara Therapeutics Inc., and Abivax SA Sponsored ADR. ;'>

Currently, the analyst consensus on Apellis Pharmaceuticals is a Moderate Buy with an average price target of $33.69, which is a -16.6% downside from current levels. In a report released today, Robert W. Baird also downgraded the stock to Hold with a $41.00 price target.

MoonLake Immunotherapeutics (MLTX)

TD Cowen analyst Phil Nadeau maintained a Buy rating on MoonLake Immunotherapeutics yesterday. The company’s shares closed last Tuesday at $18.70.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.8% and a 48.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as XOMA Royalty Corporation, Apellis Pharmaceuticals, and BioMarin Pharmaceutical. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MoonLake Immunotherapeutics with a $28.57 average price target, representing a 65.7% upside. In a report issued on March 19, Rothschild & Co Redburn also upgraded the stock to Buy with a $40.00 price target.

Read More on TRDA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).